More than 200 individuals have raised concerns about potential deaths linked to ingredients found in weight loss injections such as Wegovy and Mounjaro, as per recent data shared with health authorities.
Information gathered from the Medicine and Healthcare Products Regulatory Agency’s (MHRA) Yellow Card Scheme reveals that over 200 individuals have reported deaths they believe are connected to these medications, along with more than 150,000 reports of adverse reactions. The complaints span various brands and indicate issues like gastrointestinal problems experienced while using these products.
Public reports of deaths specifically focus on the active components of popular injections and diabetes treatments like Ozempic. The MHRA data discloses that 106,189 adverse reactions, including gastrointestinal issues, and 120 deaths have been documented regarding tirzepatide, marketed as Mounjaro. Additionally, people have reported 48,089 reactions and 59 suspected deaths related to semaglutide, the main element in the weight-loss drug Wegovy.
Semaglutide is also utilized in diabetes treatments such as Ozempic and Rybelsus. Concerning liraglutide, sold under the brand name Saxenda, a total of 4,491 adverse reactions and 37 deaths have been reportedly linked to it.
The MHRA emphasizes that reports submitted to the Yellow Card Scheme do not definitively prove that the medicine caused the reported death or reaction, only that the reporter suspects a potential connection. An MHRA spokesperson highlighted the importance of considering these reports within the context of the extensive use of GLP-1 prescriptions in the UK.
Regarding the safety of these medications, the spokesperson added that continuous evaluation is essential, incorporating emerging data and scientific research. They assured that any safety updates would be promptly communicated to patients and healthcare professionals to address any identified risks.
In response to the recent developments, Health Secretary Yvette Cooper assured the public of a robust regulatory system in place to record and analyze any adverse reactions to weight loss drugs effectively.
In the UK, three types of weight-loss injections – Wegovy, Mounjaro, and Saxenda – are currently available through the NHS, with Wegovy being the most popular choice. Research conducted by University College London in January suggested a significant usage of weight-loss drugs among the population, surpassing initial prescribing goals set by NHS England.
Professor Sarah Jackson, lead author of the study, highlighted the substantial use of weight loss drugs in the UK, emphasizing the need for detailed monitoring to track trends over time and prevent misuse outside medical supervision.
Common side effects of weight loss drugs, including constipation, diarrhoea, stomach cramps, nausea, and headaches, are outlined by NHS inform. Additionally, less common but severe side effects like vision changes, kidney issues, pancreatitis, and gallbladder problems may occur, requiring attention.
By opting for Daily Mirror as a ‘Preferred Source’ on Google News, you can access the latest news updates conveniently.
